Breaking News Instant updates and real-time market news.

MT

ArcelorMittal

$22.87

(0.00%)

, TPX

Tempur Sealy

$51.40

(0.00%)

09:40
11/30/18
11/30
09:40
11/30/18
09:40

Unusually active option classes on open November 30th

Unusual total active option classes on open include: ArcelorMittal (MT), Tempur Sealy (TPX), Splunk (SPLK), Marriott (MAR), Palo Alto Networks (PANW), iShares Silver Trust (SLV), Goldman Sachs (GS), Altria Group (MO), FXI (FXI), and SPDR Gold Trust (GLD).

MT

ArcelorMittal

$22.87

(0.00%)

TPX

Tempur Sealy

$51.40

(0.00%)

SPLK

Splunk

$102.00

(0.00%)

MAR

Marriott

$121.78

(0.00%)

PANW

Palo Alto Networks

$176.04

(0.00%)

SLV

iShares Silver Trust

$13.44

(0.00%)

GS

Goldman Sachs

$194.85

(0.00%)

MO

Altria Group

$55.94

(0.00%)

FXI

iShares China Large-Cap ETF

$41.41

(0.00%)

GLD

SPDR Gold Shares

$115.75

(0.00%)

  • 30

    Nov

  • 30

    Nov

  • 03

    Dec

  • 05

    Dec

  • 05

    Dec

  • 06

    Dec

  • 06

    Dec

  • 07

    Dec

  • 10

    Dec

  • 13

    Dec

  • 19

    Dec

  • 09

    Jan

  • 10

    Jan

MT ArcelorMittal
$22.87

(0.00%)

03/09/18
COWN
03/09/18
NO CHANGE
COWN
Cowen sees upside for entire steel group with tariff decision
Cowen analyst Novid Rassouli said he sees upside for the entire steel group following the announced decision on tariffs for imported steel and aluminum. He said the entire steel group is trading at a discount to current spot steel prices. The analyst also believes Century Aluminum (CENX) will be the biggest beneficiary on the aluminum side, as he sees it as the best vehicle to capitalize. Publicly traded companies in the steel space include U.S. Steel (X), Steel Dynamics (STLD), AK Steel (AKS), Cleveland-Cliffs (CLF), Nucor (NUE) and ArcelorMittal (MT).
04/30/18
JPMS
04/30/18
DOWNGRADE
JPMS
Neutral
Outokumpu downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Luke Nelson downgraded Outokumpu (OUTKY) to Neutral and lowered his price target for the shares to EUR 6 from EUR 11.60. ArcelorMittal (MT) remains the analyst's top pick in European Steel.
06/07/18
UBSW
06/07/18
DOWNGRADE
UBSW
Sell
ArcelorMittal downgraded to Sell from Buy at UBS
11/09/18
UBSW
11/09/18
UPGRADE
UBSW
Neutral
ArcelorMittal upgraded to Neutral from Sell at UBS
TPX Tempur Sealy
$51.40

(0.00%)

10/17/18
STFL
10/17/18
NO CHANGE
Target $60
STFL
Buy
Stifel bullish on Tempur Sealy ahead of earnings given high-end brand strength
Stifel analyst John Baugh said his holiday channel checks, discussions with trade contacts and an increased level of review activity for the Tempur-Pedic brand add up to give him increasing conviction going into Tempur Sealy's Q3 earnings report that its domestic TempurPedic sales are strong. Though he is not changing his estimates in front of the Q3 release, Baugh believes the Tempur brand is performing better than he'd thought several months ago while Sealy is now likely struggling more. He keeps a Buy rating and $60 price target on Tempur Sealy shares.
10/03/18
10/03/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Tempur Sealy (TPX) upgraded to Neutral from Sell at UBS with analyst Michael Lasser saying a potential Mattress Firm bankruptcy is likely to be positive for Tempur. 2. Stifel Financial (SF) upgraded to Outperform from Market Perform at JMP Securities with analyst Devin Ryan saying while he is not overly dismissive of the market's concerns, he believes some misconceptions exist and also thinks the stock is more than reflecting the worries, leaving the bar "incredibly low" now. 3. Wingstop (WING) upgraded to Buy from Neutral at Guggenheim with analyst Matthew DiFrisco saying he has increased confidence in Wingstop's ability to support mid-single digit same-store sales growth and double-digit expansion through 2025 following the meetings. 4. Intuit (INTU) upgraded to Outperform from In Line at Evercore ISI. 5. Michael Kors (KORS) upgraded to Buy from Neutral at Citi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/01/18
LOOP
11/01/18
NO CHANGE
Target $36
LOOP
Sell
Loop Capital affirms Sell rating on Tempur Sealy after Q3 miss
Loop Capital analyst Laura Champine maintains a Sell rating Tempur Sealy with a $36 price target after the company's Q3 results missed expectations on the top- and bottom-lines. The analyst is concerned that Tempur's price increases in 2019 to recapture higher commodity costs "may only encourage continued consumer trade-down in the company's range." It may be tough to convince consumers to trade up to higher-priced offerings in the Sealy line in particular given the aggressive financing offers customers rely on in the mattress industry and the influx of competing mattresses from Asia at compelling price points, Champine tells investors in a post-earnings research note.
10/05/18
KEYB
10/05/18
NO CHANGE
Target $75
KEYB
Overweight
Mattress Firm bankruptcy positive for Tempur Sealy, says KeyBanc
KeyBanc analyst Bradley Thomas sees this morning's announced Chapter 11 bankruptcy by Mattress Firm as a positive for Tempur Sealy. The news increases the likelihood of a re-partnership between the two companies, which would be a "major upside catalyst" for Tempur, Thomas tells investors in a research note. He believes both Mattress Firm and Tempur could benefit from a re-partnership, and that such an event could be a $2-plus earnings per share benefit to Tempur. The analyst reiterates an Overweight rating on the shares with a $75 price target. The stock in midday trading is down 3%, or $1.43, to $49.85.
SPLK Splunk
$102.00

(0.00%)

11/27/18
BMOC
11/27/18
NO CHANGE
Target $133
BMOC
Outperform
Splunk demand trends remain solid, says BMO Capital
BMO Capital analyst Keith Bachman kept his Outperform rating and $133 price target on Splunk, saying there is "upside tension" to his and to consensus estimates for October quarter billings and revenues based on the company's "solid demand trends". The analyst also anticipates the company to provide strong January quarter guidance and for the management to "devote considerable attention to billings duration on the upcoming earnings call" to answer investors' concerns about its billings duration. Bachman further points to Splunk's attractive valuation, with the stock currently trading at about 6.5-times enterprise value to revenue multiple, which is about 6% below its 3-year average.
11/30/18
PIPR
11/30/18
NO CHANGE
Target $130
PIPR
Overweight
Splunk price target raised to $130 from $120 at Piper Jaffray
Piper Jaffray analyst Alex Zukin raised his price target for Splunk to $130 and reiterates an Overweight rating on the shares. The analyst says the company last night posted the quarter he was were looking for, with its largest quarterly revenue beat in five years coupled with guidance that outperformed both in the current year and for fiscal 2020. Splunk's fundamentals continue to improve and it remains a "strategic asset trading at a discounted valuation," Zukin tells investors in a post-earnings research note titled "F3Q19 Earnings: Doug E. Fresh With the Beat as King Conte Drops the Mic."
11/30/18
JEFF
11/30/18
NO CHANGE
Target $137
JEFF
Buy
Splunk raised guidance by more than the Q3 beat, says Jefferies
Splunk exceeded fiscal Q3 expectations, raised fiscal 2019 by more than the beat, and raised its outlook for fiscal 2020, Jefferies analyst John DiFucci tells investors in a post-earnings research note. The analyst continues to view the company as a "unique asset" that represents one of the best ways to play the Big Data theme. Further, he believes the underlying business is likely stronger than it appears. The analyst keeps a Buy rating on Splunk with a $137 price target.
11/30/18
MUFG
11/30/18
NO CHANGE
Target $130
MUFG
Overweight
Splunk target raised to $130 on 'solid momentum' at MUFG
MUFG analyst Stephen Bersey raised his price target for Splunk to $130 from $128 saying the company's "streak of solid momentum continues." The analyst views last night's fiscal Q3 results as "strong," marked by a re-acceleration of license revenue growth to 44.3% year-over-year, the highest level of the fiscal year thus far. Splunk still has a long runway of growth ahead of it as its core business solutions continue to gain traction within the enterprise vertical and as the company continues to roll out new products and solutions, Bersey tells investors in a post-earnings research note. He reiterates an Overweight rating on the name.
MAR Marriott
$121.78

(0.00%)

11/20/18
ARGS
11/20/18
DOWNGRADE
ARGS
Hold
Marriott downgraded to Hold from Buy at Argus
Argus analyst John Staszak downgraded Marriott (MAR) to Hold, citing a recent slowdown in its RevPAR growth as well as the potential for the multi-year upturn in the lodging industry to end. The analyst states that the company's latest EPS beat reflected stock repurchases and "carefully managed expenses", as revenue fell 1% and North America RevPAR was up just 0.6% and below the management's prior guidance of 1.5%-2.0% growth. Staszak adds that Marriott shares have rallied over 200% since his upgrade in 2012, but believes that other consumer discretionary names such as McDonalds (MCD) offer greater return prospects.
11/27/18
GSCO
11/27/18
DOWNGRADE
Target $70
GSCO
Buy
Wyndham Hotels & Resorts downgraded to Buy from Conviction Buy at Goldman Sachs
Goldman Sachs analyst Stephen Grambling removed Wyndham Hotels & Resorts (WYN) from his firm's America's Conviction List while keeping a Buy rating on the shares. The analyst lowered his price target for the stock to $70 from $76. Grambling reduced his estimates for Wyndham to reflect incremental caution around timeshare amid softening housing data and rising rates. However, he continues to believe upside from the La Quinta acquisition, accelerating unit growth, and fee rates should all drive upside to consensus estimates and a "re-rating" versus peers. Nonetheless, Grambling sees a more attractive risk/reward in shares of Marriott (MAR).
11/27/18
11/27/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Disney (DIS) upgraded to Outperform from In-Line at Imperial Capital with analyst David Miller saying while fiscal 2019 should be a "transitional year," fiscal 2020 brings an "abundance of catalysts." 2. Citizens Financial (CFG) upgraded to Outperform from Neutral at Macquarie. 3. Parsley Energy (PE) upgraded to Buy from Neutral at Goldman Sachs with analyst John Nelson saying greater appreciation of the the company's free cash flow inflection in the second half of 2019 should drive improved investor sentiment. 4. Taubman Centers (TCO) was upgraded to Sector Perform from Underperform at Scotiabank and to Equal Weight from Underweight at Morgan Stanley. 5. Marriott (MAR) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Stephen Grambling saying the stock has been penalized recently amid Starwood integration issues, but these will prove temporary and position Marriott better in the future. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/27/18
GSCO
11/27/18
UPGRADE
GSCO
Conviction Buy
Marriott upgraded to Conviction Buy from Buy at Goldman Sachs
Goldman Sachs analyst Stephen Grambling added Marriott International to his firm's America's Conviction List while keeping a Buy rating on the shares. The analyst lowered his price target for the shares to $153 from $159. The stock has been penalized recently amid Starwood integration issues, but these will prove temporary and position Marriott better in the future, Grambling tells investors in a research note. He believes that as the disruption normalizes, net unit growth should accelerate and Marriott should post upside to consensus estimates.
PANW Palo Alto Networks
$176.04

(0.00%)

11/30/18
FBCO
11/30/18
NO CHANGE
Target $160
FBCO
Underperform
Palo Alto Networks price target cut to $160 from $185 at Credit Suisse
Credit Suisse analyst Brad Zelnick reiterated an Underperform rating on Palo Alto Networks and cut his price target to $160 following the company's "mixed" Q1 results. In a research note to investors, Zelnick says the disparity between product and billings performance continues to suggest an especially strong refresh dynamic, and while he maintains respect for Palo Alto's market leadership, strong execution and superlative messaging, he believes his secular call is just beginning to play out as firewalls cede relevance in a cloud-first world.
11/30/18
GABE
11/30/18
UPGRADE
GABE
Buy
Palo Alto Networks upgraded to Buy from Hold at Gabelli
Gabelli analyst Hendi Susanto upgraded Palo Alto to Buy citing recent shares weakness. The analyst views current valuation as attractive and remains favorable on Palo Alto's market leadership, technology platform, and competitive security platform.
11/30/18
BMOC
11/30/18
NO CHANGE
Target $205
BMOC
Market Perform
Palo Alto Networks price target lowered to $205 from $260 at BMO Capital
BMO Capital analyst Keith Bachman lowered his price target on Palo Alto Networks to $205 and kept his Market Perform rating, saying that while the company beat on Q1 earnings, its billings were in line, "which is a downtick from the outperformance in prior quarters". The analyst believes that the free cash flow multiple on Palo Alto Networks is "reasonable", but also warns about the overhang on the stock lingering because of the potential for M&A. Bachman adds that he is concerned by the "durability" of the company's billings growth, adding that his price target reduction reflects "lower free cash flow estimates and a lower multiple due to a reduced equity risk environment".
11/30/18
MAXM
11/30/18
NO CHANGE
Target $280
MAXM
Buy
Palo Alto Networks price target raised to $280 from $274 at Maxim
Maxim analyst Nehal Chokshi raised his price target on Palo Alto Networks to $280 and kept his Buy rating after "another beat and raise quarter", saying the company's strong results were driven by sequential subscription revenue growth. The analyst adds that the above-consensus guidance was the factor of the "uniqueness" of the company's Application Framework. Chokshi is also positive on Palo Alto Networks' CEO plan to extend its business "from security to the intersection of security and AI".
SLV iShares Silver Trust
$13.44

(0.00%)

GS Goldman Sachs
$194.85

(0.00%)

11/30/18
BOFA
11/30/18
DOWNGRADE
Target $225
BOFA
Neutral
Goldman Sachs downgraded to Neutral from Buy at BofA/Merrill
BofA Merrill Lynch analyst Michael Carrier downgraded Goldman Sachs to Neutral from Buy and also removed the stock from the firm's US 1 List, stating that the uncertainty around the 1MDB investigation could limit the stock's upside potential if markets stabilize. While he doesn't expect the matter to have a long-term impact on the business, Carrier does note that the timing of the investigation is unknown and it may take some time to be resolved. Based on disclosure thus far, he views the more likely outcome as a fine/settlement, though "it is impossible to know the outcome of the matter," Carrier concluded. He lowered his price target on Goldman shares to $225 from $280.
11/21/18
11/21/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Lowe's (LOW) downgraded to Hold from Buy at Stifel with analyst John Baugh saying the company's "poor" Q3 results indicate near term execution risks are higher and the macro backdrop is unlikely to improve in the near term either. 2. Goldman Sachs (GS) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Betsy Graseck citing the risks and uncertainties related to the bank being investigated for its role in raising funds for 1MDB. 3. Credit Suisse (CS) downgraded to Market Perform from Outperform at Keefe Bruyette. 4. Swatch Group (SWGAY) was downgraded to Sell from Neutral at UBS and to Sector Perform from Outperform at RBC Capital. 5. Alliant Energy (LNT) downgraded to Underperform from Neutral at BofA/Merrill with analyst Julien Dumoulin-Smith citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/21/18
11/21/18
DOWNGRADE
Target $226

Equal Weight
Goldman Sachs downgraded to Equal Weight on 1MDB probe risks at Morgan Stanley
As previously reported, Morgan Stanley analyst Betsy Graseck downgraded Goldman Sachs to Equal Weight from Overweight, citing the risks and uncertainties related to the bank being investigated for its role in raising funds for 1MDB. It is currently unclear how long the issue will take to resolve, what the fines and penalties could be and what costs Goldman will incur, said Graseck, who doesn't see the stock's multiple expanding significantly until the 1MDB issue is resolved. She lowered her price target on Goldman Sachs shares to $226 from $291.
11/21/18
MSCO
11/21/18
DOWNGRADE
MSCO
Equal Weight
Goldman Sachs downgraded to Equal Weight from Overweight at Morgan Stanley
MO Altria Group
$55.94

(0.00%)

10/23/18
10/23/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. RH (RH) initiated with an Outperform at Wedbush. 2. Altria Group (MO) initiated with a Market Perform at Bernstein. 3. Gritstone Oncology (GRTS) initiated with an Outperform at Cowen, an Overweight at Barclays, and a Neutral at Goldman Sachs. 4. Caesars (CZR) initiated with an Overweight at Morgan Stanley. 5. Atlassian (TEAM) initiated with a Hold on valuation at Needham. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/26/18
WELS
11/26/18
NO CHANGE
Target $65
WELS
Outperform
Altria Group price target lowered to $65 from $75 at Wells Fargo
Wells Fargo analyst Bonnie Herzog lowered her price target for Altria Group to $65 from $75, while reiterating an Outperform rating on the shares. The analyst notes that the stock has been hit hard in the last 10 trading days primarily due to concerns surrounding increased regulatory noise/uncertainty and decelerating cigarette industry volumes in recent Nielsen data. Herzog now feels "compelled to pound the table" on the stock given her belief that industry cigarette volumes are not as bad as feared based on feedback from her retailer contacts in her recent "Tobacco Talk" survey. The FDA's recent decision to restrict e-cigarette flavors and pursue menthol cigarette/cigar bans, while broadly concerning, does not materially impact near-term trends and importantly, the e-cigarette flavor regulations could actually benefit Altria on a relative basis, she points out. Additionally, the analyst believes Altria's valuation is very attractive with the stock trading at a 5-year low.
11/29/18
MSCO
11/29/18
NO CHANGE
Target $63
MSCO
Equal Weight
Stake in Juul could make strategic sense for Altria, says Morgan Stanley
Commenting on The Wall Street Journal's report that Altria is in talks to take a "significant minority stake" in Juul Labs, Morgan Stanley analyst Pamela Kaufman said she has no knowledge of a potential deal but that taking such a stake could make strategic sense for Altria to gain exposure to a fast growing product that poses a threat to its cigarette business. Altria does not have a robust reduced risk product portfolio and Juul's e-cigs could significantly enhance its competitive position, contends Kaufman, who also believes Altria would likely be buying in at a lower valuation than the previously reported $15B given the FDA recently prohibited flavored pods sales in convenience stores. Kaufman keeps an Equal Weight rating on Altria with a $63 price target.
10/23/18
PIPR
10/23/18
NO CHANGE
Target $75
PIPR
Overweight
Altria can post attractive double-digit earnings growth, says Piper Jaffray
Piper Jaffray analyst Michael Lavery believes pricing, tax savings and the management of spending can drive Altria Group's earnings growth to double-digits over the next three years, above the company's long-term 7%-9% growth target. The analyst considers this growth attractive, "especially with its 5.5% dividend yield." Lavery trimmed his Q3 cigarette volume decline estimate to down 5.5% and 2018 earnings per estimate to $3.95 from $3.97 to align with retail trends. He keeps an Overweight rating on Altria Group with a $75 price target.
FXI iShares China Large-Cap ETF
$41.41

(0.00%)

GLD SPDR Gold Shares
$115.75

(0.00%)

TODAY'S FREE FLY STORIES

HPQ

HP Inc.

$20.17

0.05 (0.25%)

, XRX

Xerox

$38.95

0.295 (0.76%)

20:56
11/17/19
11/17
20:56
11/17/19
20:56
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

HPQ

HP Inc.

$20.17

0.05 (0.25%)

XRX

Xerox

$38.95

0.295 (0.76%)

GOLD

Barrick Gold

$16.57

-0.095 (-0.57%)

PCG

PG&E

$7.41

0.71 (10.60%)

FOX

Fox Corp.

$33.60

0.14 (0.42%)

FOXA

Fox Corp.

$34.26

0.04 (0.12%)

SNE

Sony

$62.03

0.23 (0.37%)

BR

Broadridge

$119.80

0.485 (0.41%)

MDT

Medtronic

$112.11

2.9 (2.66%)

DIS

Disney

$144.63

-2.56 (-1.74%)

BRK.A

Berkshire Hathaway

$329,361.11

266.11 (0.08%)

BRK.B

Berkshire Hathaway

$219.74

0.38 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 26

    Nov

  • 09

    Dec

  • 07

    Jan

RCEL

Avita Medical

$8.13

-0.06 (-0.73%)

20:39
11/17/19
11/17
20:39
11/17/19
20:39
Hot Stocks
Avita Medical appoints David McIntyre CFO »

AVITA Medical announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EIDX

Eidos Therapeutics

$46.58

1.33 (2.94%)

20:37
11/17/19
11/17
20:37
11/17/19
20:37
Recommendations
Eidos Therapeutics analyst commentary  »

Piper Jaffray sees Eidos…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 21

    Nov

COO

Cooper Companies

$301.97

2.64 (0.88%)

20:30
11/17/19
11/17
20:30
11/17/19
20:30
Recommendations
Cooper Companies analyst commentary  »

Piper Jaffray reiterates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

CRM

Salesforce

$163.20

0.18 (0.11%)

20:21
11/17/19
11/17
20:21
11/17/19
20:21
Recommendations
Salesforce analyst commentary at Jefferies »

Salesforce price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Dec

  • 16

    Dec

CCMP

Cabot Microelectronics

$155.89

2.68 (1.75%)

20:15
11/17/19
11/17
20:15
11/17/19
20:15
Earnings
Breaking Earnings news story on Cabot Microelectronics »

Cabot Microelectronics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

CCMP

Cabot Microelectronics

$155.89

2.68 (1.75%)

20:15
11/17/19
11/17
20:15
11/17/19
20:15
Earnings
Cabot Microelectronics sees Q1 total revenue approximately flat »

For Q1, the company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

CCMP

Cabot Microelectronics

$155.89

2.68 (1.75%)

20:14
11/17/19
11/17
20:14
11/17/19
20:14
Earnings
Cabot Microelectronics reports Q4 EPS $1.68, consensus $1.63 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

JEF

Jefferies Financial Group

$19.08

0.16 (0.85%)

20:13
11/17/19
11/17
20:13
11/17/19
20:13
Hot Stocks
Jefferies Financial Group to sell 31% interest in National Beef to Marfrig »

Jefferies Financial Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NIO

NIO Inc.

$1.82

0.07 (4.01%)

20:11
11/17/19
11/17
20:11
11/17/19
20:11
Hot Stocks
NIO Inc. appoints Wei Feng CFO »

NIO Inc. announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOLD

Barrick Gold

$16.57

-0.095 (-0.57%)

20:09
11/17/19
11/17
20:09
11/17/19
20:09
Hot Stocks
Barrick Gold to sell 50% stake in Australian mine for $750M in cash »

Barrick Gold Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOLD

Barrick Gold

$16.57

-0.095 (-0.57%)

15:40
11/17/19
11/17
15:40
11/17/19
15:40
Periodicals
Saracen close to buying Barrick Gold mine stake for $750M, Bloomberg says »

Saracen Mineral Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESPR

Esperion

$40.51

0.67 (1.68%)

15:11
11/17/19
11/17
15:11
11/17/19
15:11
Hot Stocks
Esperion presents pooled analyses from four Phase 3 bempedoic acid studies »

Esperion announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 26

    Feb

PCG

PG&E

$7.41

0.71 (10.60%)

15:06
11/17/19
11/17
15:06
11/17/19
15:06
Hot Stocks
PG&E monitoring potential weather event that could lead to power shutoffs »

Pacific Gas and Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

XRX

Xerox

$38.95

0.295 (0.76%)

, HPQ

HP Inc.

$20.17

0.05 (0.25%)

15:04
11/17/19
11/17
15:04
11/17/19
15:04
Hot Stocks
HP unanimously rejects unsolicited Xerox proposal »

HP Inc. (HPQ) announced…

XRX

Xerox

$38.95

0.295 (0.76%)

HPQ

HP Inc.

$20.17

0.05 (0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 09

    Dec

FOX

Fox Corp.

$33.60

0.14 (0.42%)

, FOXA

Fox Corp.

$34.26

0.04 (0.12%)

14:49
11/17/19
11/17
14:49
11/17/19
14:49
On The Fly
Box Office Battle: 'Ford v Ferrari' races to top, 'Charlie's Angels' disappoints »

"Box Office Battle" is…

FOX

Fox Corp.

$33.60

0.14 (0.42%)

FOXA

Fox Corp.

$34.26

0.04 (0.12%)

LGF.A

Lionsgate

$9.67

0.315 (3.37%)

LGF.B

Lionsgate

$9.07

0.345 (3.96%)

SNE

Sony

$62.03

0.23 (0.37%)

VIA

Viacom

$26.59

1.28 (5.06%)

VIAB

Viacom

$23.07

0.59 (2.62%)

T.CA

TELUS Corp. (Toronto)

$0.00

(0.00%)

CMCSA

Comcast

$44.54

-0.93 (-2.05%)

CMCSK

Comcast

$0.00

(0.00%)

DIS

Disney

$144.63

-2.56 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

JNJ

Johnson & Johnson

$134.97

3.99 (3.05%)

13:36
11/17/19
11/17
13:36
11/17/19
13:36
Periodicals
J&J rushed to test baby powder and got complicated results, WSJ says »

In October, Johnson &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

  • 07

    Dec

  • 21

    Jan

BA

Boeing

$371.55

4.25 (1.16%)

13:24
11/17/19
11/17
13:24
11/17/19
13:24
Periodicals
Boeing 737 makes emergency landing after engine malfunction, NY Post says »

A Canada-bound flight…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$47.46

0.09 (0.19%)

13:17
11/17/19
11/17
13:17
11/17/19
13:17
Hot Stocks
Data shows AstraZeneca's Brilinta reduces risks of clinically relevant bleeding »

New results from a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 07

    Dec

LLY

Eli Lilly

$113.18

1.8 (1.62%)

13:11
11/17/19
11/17
13:11
11/17/19
13:11
Hot Stocks
Analysis shows Jardiance decreased risk of hospitalization for heart failure »

A new interim analysis of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

AZN

AstraZeneca

$47.46

0.09 (0.19%)

13:09
11/17/19
11/17
13:09
11/17/19
13:09
Hot Stocks
AstraZeneca says data shows Farxiga reduces risks in heart failure patients »

AstraZeneca announced new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 07

    Dec

BA

Boeing

$371.55

4.25 (1.16%)

13:05
11/17/19
11/17
13:05
11/17/19
13:05
Hot Stocks
Boeing, Biman announce order for two 787-9 Dreamliner jets »

Boeing and Biman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBIO

BridgeBio

$28.26

0.55 (1.98%)

, EIDX

Eidos Therapeutics

$46.58

1.33 (2.94%)

13:03
11/17/19
11/17
13:03
11/17/19
13:03
Hot Stocks
BridgeBio, Eidos present 'positive' data from Phase 2 clinical trial of AG10 »

BridgeBio Pharma (BBIO)…

BBIO

BridgeBio

$28.26

0.55 (1.98%)

EIDX

Eidos Therapeutics

$46.58

1.33 (2.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 21

    Nov

CLBS

Caladrius

$2.64

-0.06 (-2.22%)

13:01
11/17/19
11/17
13:01
11/17/19
13:01
Hot Stocks
Caladrius reports 'positive' results for CLBS16 from ESCaPE-CMD trial »

Caladrius Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KNSA

Kiniksa

$6.52

0.1 (1.56%)

12:59
11/17/19
11/17
12:59
11/17/19
12:59
Hot Stocks
Kiniksa presents Rilonacept final Phase 2 clinical data »

Kiniksa Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 21

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.